Emine Pirim GÖRGÜN, Hülya TOKER, Ömer POYRAZ

Effect of Non-surgical Periodontal Treatment on Gingival Crevicular Fluid Interleukin-1beta and Interleukin-37 in Different Periodontal Diseases

Objective: Interleukin-37 (IL-37), which is a natural inhibitor of innate immunity, is correlated with chronic inflammation and some autoimmune diseases. Proinflammatory cytokines, for example, interleukin-1beta (IL-1β), which plays a key part in the periodontium, can induce IL-37. This study aimed to investigate the effect of non-surgical periodontal treatment on gingival crevicular fluid (GCF) IL37 and IL-1β levels in generalized aggressive periodontitis (G-AgP) and generalized chronic periodontitis (GCP). Materials and Methods: Thirty-five patients with G-AgP, 30 patients with GCP and 30 volunteers with healthy periodontal status (C) were included in this research. Patient groups received scaling and root planning with periodontal hand instrumentations. Clinical periodontal parameters and GCF samples were collected at baseline and at six weeks following SRP. Biomarker levels in GCF were analysed by enzyme-linked immunosorbent assay. Results: Both periodontitis groups exhibited significant improvement in clinical parameters (p

Farklı Periodontal Hastalıklarda Cerrahisiz Periodontal Tedavinin Diş Eti Oluğu Sıvısı İnterlökin-1beta ve İnterlökin-37 Üzerine Etkisi

Amaç: Doğal bağışıklığın doğal bir inhibitörü olan interlökin-37 (IL-37), kronik enflamasyon ve bazı otoimmün hastalıklarla ilişkilidir. Periodonsiyumda önemli bir rol oynayan IL-1beta (IL-1β) gibi pro-enflamatuvar sitokinler, IL-37’yi indükleyebilir. Bu araştırmada, cerrahi olmayan periodontal tedavinin generalize agresif (G-AgP) ve generalize kronik periodontitiste (GCP) diş eti oluğu sıvısı (DOS) IL-37 ve IL-1β düzeyleri üzerine etkilerinin araştırılması amaçlanmıştır. Gereç ve Yöntemler: Otuz beş G-AgP hastası, 30 GCP hastası ve 30 periodontal olarak sağlıklı gönüllü (C) çalışmaya dahil edildi. Hasta gruplarına periodontal el aletleri ile detertraj ve kök yüzeyi düzleştirmesi uygulandı. Klinik periodontal parametrelerin ve DOS örneklerinin toplanması başlangıçta ve tedaviden 6 hafta sonra gerçekleştirildi. DOS’daki biyobelirteç seviyeleri enzim bağlı immünosorbent deneyi ile analiz edildi. Bulgular: Her iki periodontitis grubu da klinik parametrelerde anlamlı düzelme gösterdi (p

PDF

___

1. Dentino A, Lee S, Mailhot J, Hefti AF. Principles of periodontology. Periodontol 2000. 2013; 61: 16-53.

2. Hasan A, Palmer R. A clinical guide to periodontology: Pathology of periodontal disease. Br Dent J 2014; 216: 457-61.

3. Nędzi-Gora M, Kowalski J, Gorska R. The immune response in periodontal tissues. Arch Immunol Ther Exp (Warsz) 2017; 65: 421-9.

4. Bosshardt DD. The periodontal pocket: pathogenesis, histopathology and consequences. Periodontol 2000. 2018; 76: 43-50.

5. Henderson B, Kaiser F. Bacterial modulators of bone remodeling in the periodontal pocket. Periodontol 2000 2018; 76: 97-108.

6. Zein Elabdeen HR, Mustafa M, Ali R, Bolstad AI. Cytokine profile in gingival crevicular fluid and plasma of patients with aggressive periodontitis. Acta Odontol Scand 2017; 75: 616-22.

7. Gilowski L, Wiench R, Plocica I, Krzeminski TF. Amount of interleukin-1β and interleukin-1 receptor antagonist in periodontitis and healthy patients. Arch Oral Biol 2014; 59: 729-34.

8. Al‐Shammari KF, Giannobile WV, Aldredge WA, Iacono VJ, Eber RM, Wang HL, et al. Effect of non‐surgical periodontal therapy on C‐telopeptide pyridinoline cross‐links (ICTP) and interleukin‐1 levels. J. J Periodontol 2001; 72: 1045-51.

9. Faizuddin M, Bharathi S, Rohini N. Estimation of interleukin‐1β levels in the gingival crevicular fluid in health and in inflammatory periodontal disease. J Periodontal Res 2003; 38: 111-4.

10. Hou LT, Liu CM, Rossomando EF. Crevicular interleukin‐1β in moderate and severe periodontitis patients and the effect of phase I periodontal treatment. J Clin Periodontol 1995; 22: 162-7.

11. Engebretson SP, Grbic JT, Singer R, Lamster IB. GCF IL‐1β profiles in periodontal disease. J Clin Periodontol 2002; 29: 48-53.

12. Reinhardt RA, Stoner JA, Golub LM, Lee HM, Nummikoski PV, Sorsa T, et al. Association of gingival crevicular fluid biomarkers during periodontal maintenance with subsequent progressive periodontitis. J Periodontol 2010; 81: 251-9.

13. Toker H, Poyraz O, Eren K. Effect of periodontal treatment on IL‐1β, IL‐1ra, and IL‐10 levels in gingival crevicular fluid in patients with aggressive periodontitis. J Clin Periodontol 2008; 35: 507-13.

14. Rosalem W, Rescala B, Teles R, Fischer R, Gustafsson A, Figueredo C. Effect of non‐surgical treatment on chronic and aggressive periodontitis: clinical, immunologic, and microbiologic findings. J Periodontol 2011; 82: 979-89.

15. Wang L, Quan Y, Yue Y, Heng X, Che F. Interleukin-37: A crucial cytokine with multiple roles in disease and potentially clinical therapy. Oncol Lett 2018; 15: 4711-9.

16. Song L, Qiu F, Fan Y, Ding F, Liu H, Shu Q, et al. Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus. J Clin Immunol 2013; 33: 111-7.

17. Boraschi D, Lucchesi D, Hainzl S, Leitner M, Maier E, Mangelberger D, et al. IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw 2011; 22: 127-47.

18. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010; 11: 1014-22.

19. Ye L, Ji L, Wen Z, Zhou Y, Hu D, Li Y, et al. IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity. J Transl Med 2014; 12:

20. Xu W-D, Zhao Y, Liu Y. Insights into IL-37, the role in autoimmune diseases. Autoimmun Rev 2015; 14: 1170-5.

21. Sağlam M, Köseoğlu S, Savran L, Pekbağriyanik T, Sağlam G, Sütçü R. Levels of interleukin‐37 in gingival crevicular fluid, saliva, or plasma in periodontal disease. J Periodontal Res 2015; 50: 614-21.

22. Talmac AC, Calisir M, Eroglu EG, Ertugrul AS. Effects of Er, Cr: YSGG and diode lasers on clinical parameters and gingival crevicular fluid IL-1β and IL-37 levels in generalized aggressive periodontitis. Mediators Inflamm 2019; 2019: 2780794.

23. Löe H. The gingival index, the plaque index and the retention index systems. J Periodontol 1967; 38: 610-6.

24. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol 1999; 4: 1-6.

25. 25. Caton JG, Armitage G, Berglundh T, Chapple IL, Jepsen S, Kornman KS, et al. A new classification scheme for periodontal and peri‐implant diseases and conditions–Introduction and key changes from the 1999 classification. J Periodontol 2018; 89: S1-S8.

26. Loe H. The Gingival Index, the Plaque Index and the Retention Index Systems. Periodontol 1967; 38:Suppl: 610-6.

27. Lindhe J, Nyman S, Lang N. Treatment planning. CPID 2003; 3: 420-37.

28. Özçaka Ö, Nalbantsoy A, Buduneli N. Interleukin‐17 and interleukin‐18 levels in saliva and plasma of patients with chronic periodontitis. J Periodontal Res 2011; 46: 592-8.

29. Champagne CM, Buchanan W, Reddy MS, Preisser JS, Beck JD, Offenbacher S. Potential for gingival crevice fluid measures as predictors of risk for periodontal diseases. Periodontol 2000. 2003; 31: 167-80.

30. Page RC. Host response tests for diagnosing periodontal diseases. J Periodontol 1992; 63(4 Suppl): 356-66.

31. Genco RJ. Host responses in periodontal diseases: current concepts. J Periodontol 1992; 63(4 Suppl): 338-55.

32. Figueredo C, Ribeiro M, Fischer R, Gustafsson A. Increased interleukin-1β concentration in gingival crevicular fluid as a characteristic of periodontitis. J Periodontol 1999; 70: 1457-63.

33. Gamonal J, Acevedo A, Bascones A, Jorge O, Silva A. Levels of interleukin-1β,-8, and-10 and RANTES in gingival crevicular fluid and cell populations in adult periodontitis patients and the effect of periodontal treatment. J Periodontol 2000; 71: 1535-45.

34. Oh H, Hirano J, Takai H, Ogata Y. Effects of initial periodontal therapy on interleukin-1β level in gingival crevicular fluid and clinical periodontal parameters. J Oral Sci 2015; 57: 67-71.

35. Stashenko P, Dewhirst FE, Rooney ML, Desjardins LA, Heeley JD. Interleukin‐1β is a potent inhibitor of bone formation in vitro. J Bone Miner Res 1987; 2: 559-65.

36. Zhao M, Hu Y, Jin J, Yu Y, Zhang S, Cao J, et al. Interleukin 37 promotes angiogenesis through TGF-β signaling. Sci Rep 2017; 7: 6113.

37. Kumar S, Hanning CR, Brigham-Burke MR, Rieman DJ, Lehr R, Khandekar S, et al. Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-γ production. Cytokine 2002; 18: 61-71.

38. Li C, Zhao P, Sun X, Che Y, Jiang Y. Elevated levels of cerebrospinal fluid and plasma interleukin-37 in patients with Guillain-Barré syndrome. Mediators Inflamm 2013; 2013: 639712.

39. Ji Q, Zeng Q, Huang Y, Shi Y, Lin Y, Lu Z, et al. Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome. Mediators Inflamm 2014; 2014: 165742.

40. Offenbacher S, Jiao Y, Kim SJ, Marchesan J, Moss KL, Jing L, et al. GWAS for Interleukin-1β levels in gingival crevicular fluid identifies IL37 variants in periodontal inflammation. Nat Commun 2018; 9: 3686.

41. Zhao P-W, Jiang W-G, Wang L, Jiang Z-Y, Shan Y-X, Jiang Y-F. Plasma levels of IL-37 and correlation with TNF-α, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis. PLoS One 2014; 9: e95346.

42. Saeed J, Kitaura H, Kimura K, Ishida M, Sugisawa H, Ochi Y, et al. IL-37 inhibits lipopolysaccharide-induced osteoclast formation and bone resorption in vivo. Immunol Lett 2016; 175: 8-15.

43. Zhao M, Hu Y, Shou J, Su SB, Yang J, Yang T. IL-37 impairs host resistance to listeria infection by suppressing macrophage function. Biochem Biophys Res Commun 2017; 485: 563-8.

44. Tsai Y-C, Tsai T-F. Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness. Ther Adv Musculoskelet Dis 2017; 9: 277-94